The abstract is read at the publisher; the summary is JClub's.
CD38-high chronic lymphocytic leukemia cells are linked to a CD38–NAMPT–p21 survival axis that supports resistance to fludarabine and hypoxia.
- Why it matters: CD38 is a poor-prognosis marker in CLL, but how it enables treatment failure under cytotoxic and low-oxygen stress has been unclear.
- What they did: In MEC-1 cells engineered to express CD38, CD38 NADase activity increased NAMPT and AKT activation and was associated with cytoplasmic p21 accumulation; the phenotype was lost with a catalytically inactive CD38 mutant and reversed by FK866 or UC2288.
- The result: Single-cell RNA-seq and larger primary CLL cohorts showed CD38-positive cells with higher NAMPT and stress-response signaling, and NAMPT expression linked to AKT and hypoxia signatures, supporting CD38-dependent stress adaptation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.